Dendritic cells (DCs) exhibit a specialized antigen-presenting function and play crucial roles
in both innate and adaptive immune responses. Due to their ability to cross-present tumor …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Chromosomal instability (CIN) drives cancer cell evolution, metastasis and therapy
resistance, and is associated with poor prognosis. CIN leads to micronuclei that release …

The clinical utility of stimulator of interferon genes (STING) agonists has been limited due to
poor tumour-targeting and unwanted toxicity following systemic delivery. Here we describe a …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Develo** novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

The stimulator of interferon genes (STING) cellular signaling pathway is a promising target
for cancer immunotherapy. Activation of the intracellular STING protein triggers the …

Stimulator of interferons genes (STING), which is crucial for the secretion of type I interferons
and proinflammatory cytokines in response to cytosolic nucleic acids, plays a key role in the …

Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think
about cancer treatment. Even so, for most types of cancer, only a minority of patients …